Jacob Sands

Jacob Sands is an emerging lung cancer expert focusing on mechanisms of acquired resistance to osimertinib, particularly the C797S mutation that prevents covalent binding of third-generation EGFR inhibitors. His translational research evaluates allosteric and fourth-generation EGFR inhibitors designed to overcome C797S-mediated resistance. He has contributed to studies characterizing compound mutations affecting multiple EGFR domains simultaneously. His work helps define optimal sequencing strategies for patients progressing on osimertinib.